Wellbutrin News and Research

RSS
Wellbutrin is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder and for prevention of autumn-winter seasonal depression (seasonal affective disorder).
Impax third quarter net income increases from $6.7 million to $75.2 million

Impax third quarter net income increases from $6.7 million to $75.2 million

Mylan subsidiary launches Bupropion Hydrochloride Extended-release Tablets

Mylan subsidiary launches Bupropion Hydrochloride Extended-release Tablets

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail second-quarter total revenues increase 23% to $238.8 million

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

Caraco Pharmaceutical Laboratories begins marketing bupropion hydrochloride extended release tablets

Caraco Pharmaceutical Laboratories begins marketing bupropion hydrochloride extended release tablets

Actavis Group receives FDA approval to market Bupropion HCl SR tablets

Actavis Group receives FDA approval to market Bupropion HCl SR tablets

Combination therapy for severe depression

Combination therapy for severe depression

Biovail reports 27% increase in first-quarter 2010 total revenues

Biovail reports 27% increase in first-quarter 2010 total revenues

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

American Lung Association's report examines lung cancer among African Americans

American Lung Association's report examines lung cancer among African Americans

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Mylan Pharmaceuticals' ANDA for generic Wellbutrin SR receives FDA final approval

Mylan Pharmaceuticals' ANDA for generic Wellbutrin SR receives FDA final approval

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

USFDA approves Sun Pharmaceutical Industries' ANDA for generic Wellbutrin SR Extended Release tablets

USFDA approves Sun Pharmaceutical Industries' ANDA for generic Wellbutrin SR Extended Release tablets

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Watson Pharmaceuticals' fourth-quarter net revenue rises 22%

Watson Pharmaceuticals' fourth-quarter net revenue rises 22%

Biovail comments on Teva Pharmaceutical's proposed Budeprion XL trial

Biovail comments on Teva Pharmaceutical's proposed Budeprion XL trial